Biosergen AB BIOSGN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- SEK 0.35
- Day Range
- SEK 0.31–0.35
- 52-Week Range
- SEK 0.27–5.73
- Bid/Ask
- SEK 0.32 / SEK 0.34
- Market Cap
- SEK 44.99 Mil
- Volume/Avg
- 91,320 / 75,151
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Biosergen AB is a biotech company developing innovative antifungal drugs based on latest biopharmaceutical research and development from laboratory facilities in Trondheim, Norway, and several other places worldwide. The company is developing BSG005, a potentially disruptive antifungal drug, which has demonstrated significant safety and potency advantages over competing antifungals.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 4
- Website
- https://www.biosergen.net
Valuation
|
Metric
|
BIOSGN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.00 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BIOSGN
|
|---|---|
Quick Ratio | 2.87 |
Current Ratio | 2.87 |
Interest Coverage | — |
Quick Ratio
BIOSGN
Profitability
|
Metric
|
BIOSGN
|
|---|---|
Return on Assets (Normalized) | −134.43% |
Return on Equity (Normalized) | −275.17% |
Return on Invested Capital (Normalized) | −276.14% |
Return on Assets
BIOSGN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Rwfhlvqww | Frjrx | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xksstbsp | Lwhyq | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Drbjzgyr | Zcccyg | $99.5 Bil | |
MRNA
| Moderna Inc | Pxgxtjx | Ffxfp | $38.8 Bil | |
ARGX
| argenx SE ADR | Rzpsmwcxr | Lnrcr | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Qqkjzjs | Cdlsy | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Hwljzvfqt | Dgsxntz | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Gtygbncv | Fvspy | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Jqvvpbzx | Ygqxzk | $12.5 Bil | |
INCY
| Incyte Corp | Fnctxnlw | Nndcyw | $11.6 Bil |